Overall survival of patients with cHL who progress after
autologous stem cell transplant: results in the novel agent era

J 2023

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

DESAI, Sanjal H, Michael A SPINNER, Andrew M EVENS, Alice SYKOROVA, Veronika BACHANOVA et. al.

Basic information

Original name

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

Authors

DESAI, Sanjal H, Michael A SPINNER, Andrew M EVENS, Alice SYKOROVA, Veronika BACHANOVA, Gaurav GOYAL, Brad KAHL, Kathleen DORRITIE, Jacues AZZI, Vaishalee P KENKRE, Cheryl CHANG, Jozef MICHALKA (703 Slovakia, belonging to the institution), Stephen M ANSELL, Brendon FUSCO, Nuttavut SUMRANSUB, Haris HATIC, Raya SABA, Uroosa IBRAHAM, Elyse I HARRIS, Harsh SHAH, Nina WAGNER-JOHNSTON, Sally ARAI, Grzegorz S NOWAKOWSKI, Heidi MOCIKOVA, Deepa JAGADEESH, Kristie A BLUM, Catherine DIEFENBACH, Siddharth IYENGAR, K C RAPPAZZO, Firas BAIDOUN, Yun CHOI, Vit PROCHAZKA, Ranjana H ADVANI and Ivana MICALLEF

Edition

Blood advances, AMSTERDAM, ELSEVIER, 2023, 2473-9529

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.500 in 2022

RIV identification code

RIV/00216224:14110/23:00133402

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1182/bloodadvances.2023011205

UT WoS

001134654800001

Keywords in English

cHL; patients; survival; autologous stem cell transplant

Abstract

V originále

In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.

Citovat

DESAI, Sanjal H, Michael A SPINNER, Andrew M EVENS, Alice SYKOROVA, Veronika BACHANOVA, Gaurav GOYAL, Brad KAHL, Kathleen DORRITIE, Jacues AZZI, Vaishalee P KENKRE, Cheryl CHANG, Jozef MICHALKA, Stephen M ANSELL, Brendon FUSCO, Nuttavut SUMRANSUB, Haris HATIC, Raya SABA, Uroosa IBRAHAM, Elyse I HARRIS, Harsh SHAH, Nina WAGNER-JOHNSTON, Sally ARAI, Grzegorz S NOWAKOWSKI, Heidi MOCIKOVA, Deepa JAGADEESH, Kristie A BLUM, Catherine DIEFENBACH, Siddharth IYENGAR, K C RAPPAZZO, Firas BAIDOUN, Yun CHOI, Vit PROCHAZKA, Ranjana H ADVANI and Ivana MICALLEF. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood advances. AMSTERDAM: ELSEVIER, 2023, vol. 7, No 23, p. 7295-7303. ISSN 2473-9529. Available from: https://dx.doi.org/10.1182/bloodadvances.2023011205.

@article{2368941,
   author = {Desai, Sanjal H and Spinner, Michael A and Evens, Andrew M and Sykorova, Alice and Bachanova, Veronika and Goyal, Gaurav and Kahl, Brad and Dorritie, Kathleen and Azzi, Jacues and Kenkre, Vaishalee P and Chang, Cheryl and Michalka, Jozef and Ansell, Stephen M and Fusco, Brendon and Sumransub, Nuttavut and Hatic, Haris and Saba, Raya and Ibraham, Uroosa and Harris, Elyse I and Shah, Harsh and WagnerandJohnston, Nina and Arai, Sally and Nowakowski, Grzegorz S and Mocikova, Heidi and Jagadeesh, Deepa and Blum, Kristie A and Diefenbach, Catherine and Iyengar, Siddharth and Rappazzo, K C and Baidoun, Firas and Choi, Yun and Prochazka, Vit and Advani, Ranjana H and Micallef, Ivana},
   article_location = {AMSTERDAM},
   article_number = {23},
   doi = {http://dx.doi.org/10.1182/bloodadvances.2023011205},
   keywords = {cHL; patients; survival; autologous stem cell transplant},
   language = {eng},
   issn = {2473-9529},
   journal = {Blood advances},
   title = {Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era},
   url = {https://ashpublications.org/bloodadvances/article/7/23/7295/497969/Overall-survival-of-patients-with-cHL-who-progress},
   volume = {7},
   year = {2023}
}

TY  - JOUR
ID  - 2368941
AU  - Desai, Sanjal H - Spinner, Michael A - Evens, Andrew M - Sykorova, Alice - Bachanova, Veronika - Goyal, Gaurav - Kahl, Brad - Dorritie, Kathleen - Azzi, Jacues - Kenkre, Vaishalee P - Chang, Cheryl - Michalka, Jozef - Ansell, Stephen M - Fusco, Brendon - Sumransub, Nuttavut - Hatic, Haris - Saba, Raya - Ibraham, Uroosa - Harris, Elyse I - Shah, Harsh - Wagner-Johnston, Nina - Arai, Sally - Nowakowski, Grzegorz S - Mocikova, Heidi - Jagadeesh, Deepa - Blum, Kristie A - Diefenbach, Catherine - Iyengar, Siddharth - Rappazzo, K C - Baidoun, Firas - Choi, Yun - Prochazka, Vit - Advani, Ranjana H - Micallef, Ivana
PY  - 2023
TI  - Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
JF  - Blood advances
VL  - 7
IS  - 23
SP  - 7295-7303
EP  - 7295-7303
PB  - ELSEVIER
SN  - 24739529
KW  - cHL
KW  - patients
KW  - survival
KW  - autologous stem cell transplant
UR  - https://ashpublications.org/bloodadvances/article/7/23/7295/497969/Overall-survival-of-patients-with-cHL-who-progress
N2  - In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
ER  -

DESAI, Sanjal H, Michael A SPINNER, Andrew M EVENS, Alice SYKOROVA, Veronika BACHANOVA, Gaurav GOYAL, Brad KAHL, Kathleen DORRITIE, Jacues AZZI, Vaishalee P KENKRE, Cheryl CHANG, Jozef MICHALKA, Stephen M ANSELL, Brendon FUSCO, Nuttavut SUMRANSUB, Haris HATIC, Raya SABA, Uroosa IBRAHAM, Elyse I HARRIS, Harsh SHAH, Nina WAGNER-JOHNSTON, Sally ARAI, Grzegorz S NOWAKOWSKI, Heidi MOCIKOVA, Deepa JAGADEESH, Kristie A BLUM, Catherine DIEFENBACH, Siddharth IYENGAR, K C RAPPAZZO, Firas BAIDOUN, Yun CHOI, Vit PROCHAZKA, Ranjana H ADVANI and Ivana MICALLEF. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. \textit{Blood advances}. AMSTERDAM: ELSEVIER, 2023, vol.~7, No~23, p.~7295-7303. ISSN~2473-9529. Available from: https://dx.doi.org/10.1182/bloodadvances.2023011205.

Detailed Information on Publication Record